Cytochrome P450 2B6 (CYP2B6) Genotyping
The cytochrome P450 (CYP450) enzymes metabolize the majority of drugs as well as organic compounds in our body. Most of CYP450 enzyme family members are expressed in the liver. The expression levels and/or activities of CYPs of each individual are affected by factors like genetic polymorphism, disease condition, and inducing or inhibitory chemicals. Evidence has shown that genetic polymorphisms of different CYP genes, which largely depend on ethnicity, are clinically important regarding drug dosing, drug efficacy, and adverse drug reactions (ADRs).
CYP2B6 had been thought to be a very minor portion of total cytochrome activity. However, recently it has been show that it contributes up to about 2-10% of total hepatic CYP450 proteins. Substrates of CYP2B6 include a large number of clinically used drugs and environmental chemicals. Therapeutically important substances include the anticancer prodrug cyclophosphamide, anti-HIV drug efavirenz, antidepressant agent bupropion, the anesthetics propofol and ketamine, the μ-opioid agonist methadone, and others. Another important role of CYP2B6 is to detoxify environmental chemicals and pollutants in the human body, in particular oxidation of organophosphorus insecticides. Among many other toxicants, the list includes the endocrine disruptor methoxychlor, and the well-known insect repellent DEET.
To date, numerous variants have been identified in this polymorphic CYP2B6 gene. 29 star alleles with known amino acid changes or functional effects have been documented. The most frequently seen allele is the *6 (15-60% across different races) with accompanying changes in its coding sequence and promoter region. It decreases both the expression level and enzymatic activity of CYP2B6. CYP2B6 variation *4, in contrast, is seen in 2-6% of people and causes increased expression and enzymatic activity. Another functionally important variation is *18, which is a functionally null allele seen in 4-12% of the African population. At least 12 other alleles with low or zero enzymatic activity have been found in the CYP2B6 gene.
- Manage the therapeutic outcome of anti-HIV agents such as efavirenz and nevirapine.
- Determining a therapeutic strategy for drugs metabolized by CYP2B6
CYP2B6 variants *4, *22 cause increased expression and enzymatic activity
Decreased expression or enzymatic activity of CYP2B6 is seen in *5, *6, *8, *11, *12, *13, *14, *15, *16, *18, *19, *20, *21, *26, *27, *28.
Drug Substrates for CYP2B6:
- 3,4-methylenedioxymethamphetamine, aflatoxin b1, artemisinin, bupropion, cyclophosphamide, diazepam, efavirenz, ifosfamide, ketamine, meperidine, mephenytoin, methadone, midazolam, nevirapine, nicotine, propofol, selegiline, tamoxifen
Drug Inhibitors for CYP2B6:
- clopidogrel, ethinyl estradiol, thiotepa, ticlopidine
Drug Inducer for CYP2B6:
- carbamazepine, cyclophosphamide, efavirenz, nevirapine, phenobarbital, phenytoin, rifampin
CYP2B6 \*1/\*1 (Normal metabolizer)
Different collection methods are acceptable: buccal swab and peripheral blood (EDTA) or saliva.
Whole blood collected in lavender top tube (EDTA) or any anticoagulant collection devices.
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
- J Pharmacol Exp Ther. 2004 Oct;311(1):34-43. [PMID: 15190123]
- Pharmacol Ther. 2013 Apr;138(1):103-41. [PMID: 23333322]
- Pharmacogenetics. 2004 Apr;14(4):225-38. [PMID: 15083067]
- Arch Pharm Res. 2011 Nov;34(11):1799-816. [PMID: 22139682]
- Curr Drug Metab. 2009 Sep;10(7):730-53. [PMID: 19702527]
- Curr Drug Metab, 2008 Sep; 9(7), 598-610. [PMID: 2605793]